Pepgen presents data from its duchenne muscular dystrophy program at world muscle society congress

Boston, oct. 13, 2022 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced the presentation of data from its duchenne muscular dystrophy program. the data are featured in a poster at the 27th international hybrid annual congress of the world muscle society taking place in halifax, nova scotia, canada from october 11-15, 2022.
PEPG Ratings Summary
PEPG Quant Ranking